Hoffman Richard M, Harlan Linda C, Klabunde Carrie N, Gilliland Frank D, Stephenson Robert A, Hunt William C, Potosky Arnold L
Medicine Service, New Mexico VA Health Care System, Albuquerque, NM 87108, USA.
J Gen Intern Med. 2003 Oct;18(10):845-53. doi: 10.1046/j.1525-1497.2003.21105.x.
We examined whether there were racial differences in initial treatment for clinically localized prostate cancer and investigated whether demographic, socioeconomic, clinical, or tumor characteristics could explain any racial differences.
Prospective cohort study.
Population-based tumor registries in Connecticut, Los Angeles, and Atlanta.
We evaluated 1144 African-American and non-Hispanic white men, aged 50 to 74 years, with clinically localized cancer diagnosed between October 1994 and October 1995.
We obtained demographic, socioeconomic, and clinical data from patient surveys and medical record abstractions. We reported adjusted percentages for receiving treatment derived from multinomial logistic regression. We found an interaction between race and tumor aggressiveness. Among men with more aggressive cancers (PSA > or = 20 ng/mL or Gleason score > or = 8), African Americans were less likely to undergo radical prostatectomy than non-Hispanic whites (35.2% vs 52.0%), but more likely to receive conservative management (38.9% vs 16.3%, P=.003). Among the 71% of subjects with less aggressive cancers, African Americans and non-Hispanic whites were equally likely to receive either radical prostatectomy or radiation therapy (80.0% vs 84.5%, P=.2).
African Americans with more aggressive cancers were less likely to undergo radical prostatectomy and more likely to be treated conservatively. These treatment differences may reflect African Americans' greater likelihood for presenting with pathologically advanced cancer for which surgery has limited effectiveness. Among men with less aggressive cancers-the majority of cases-there were no racial differences in undergoing radical prostatectomy or radiation therapy.
我们研究了临床局限性前列腺癌的初始治疗是否存在种族差异,并调查了人口统计学、社会经济、临床或肿瘤特征能否解释任何种族差异。
前瞻性队列研究。
康涅狄格州、洛杉矶和亚特兰大基于人群的肿瘤登记处。
我们评估了1144名年龄在50至74岁之间的非裔美国人和非西班牙裔白人男性,他们在1994年10月至1995年10月期间被诊断为临床局限性癌症。
我们从患者调查和病历摘要中获取了人口统计学、社会经济和临床数据。我们报告了通过多项逻辑回归得出的接受治疗的调整百分比。我们发现种族与肿瘤侵袭性之间存在相互作用。在患有侵袭性更强癌症(前列腺特异性抗原[PSA]≥20 ng/mL或 Gleason评分≥8)的男性中,非裔美国人接受根治性前列腺切除术的可能性低于非西班牙裔白人(35.2%对52.0%),但接受保守治疗的可能性更高(38.9%对16.3%,P = 0.003)。在71%患有侵袭性较弱癌症的受试者中,非裔美国人和非西班牙裔白人接受根治性前列腺切除术或放射治疗的可能性相同(80.0%对84.5%,P = 0.2)。
患有侵袭性更强癌症的非裔美国人接受根治性前列腺切除术的可能性较小,而接受保守治疗的可能性更大。这些治疗差异可能反映出非裔美国人更有可能出现病理上晚期的癌症,而手术对此类癌症的疗效有限。在患有侵袭性较弱癌症的男性中(大多数病例),接受根治性前列腺切除术或放射治疗不存在种族差异。